The Liposome Company Plans Product In-Licensing To Combat Evacet Delays
Executive Summary
The Liposome Company plans to buy or in-license a product from another company to compensate for delays in the approval of Evacet for the treatment of metastatic breast cancer, CEO Charles Baker told analysts.